← Acumen Pharmaceuticals, Inc. (ABOS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Acumen Pharmaceuticals, Inc. (ABOS)
Biological Products, (No Diagnostic Substances) · market cap $176M · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-15 (est.)
Phase 2
Pipeline
1
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Acumen Pharmaceuticals (ABOS) is a clinical-stage biotech with a single disclosed asset, sabirnetug, in Phase 2 for Alzheimer's Disease. The company carries a ~$190M market cap, $51.8M in cash, and a critically short 6.4-month runway, with a key Phase 2 data readout estimated for mid-October 2026. At 61 employees and no revenue, Acumen is a pure binary-catalyst vehicle ahead of what may be its most consequential data event.
The catalyst path
- 2026-10-15 (est.)Phase 2 · sabirnetugimp 7/10
- 2026-11-11 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| sabirnetug | Phase 2 | Alzheimer Disease |
Price & technical context
3-month
-23.6%
6-month
-24.4%
12-month
+16.6%
52-wk range
$1.55–$3.37
vs 50-day MA
-21.8%
vs 200-day MA
-18.7%
Realized vol
81.8%
Max drawdown
-72.5%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ABOS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.